Key Highlights
- $40M Series A financing closed, led by Khosla Ventures and Ahren Innovation Capital.
- Funds to develop lead candidate RLS-1496 for chronic atopic dermatitis and psoriasis, beginning Phase 1 studies.
- Investment boosts Rubedo’s innovative approach in targeting senescent cells involved in diseases like idiopathic pulmonary fibrosis.
Source: Business Wire
Notable Quotes
- “This significant influx of financing will allow us to advance our first clinical candidate into human studies,” – Marco Quarta, CEO & Co-Founder at Rubedo Life Sciences
- “Rubedo is targeting senescent, or aging, cells that drive age-related diseases. This first trial can bring us another step closer to achieving better healthspan,” – Alex Morgan, Partner at Khosla Ventures
- “We believe that Rubedo’s transformative approach to targeting senescent cells is an impressive step towards the development of chronic age-related therapies,” – Alice Newcombe Ellis, Founding & General Partner at Ahren Innovation Capital
SoHC's Take
Rubedo Life Sciences’ latest funding round is a pivotal moment for the company and for the field of biopharmaceuticals focused on age-related conditions. With a strong team and cutting-edge technology, Rubedo is well-positioned to lead the way in developing therapies that not only treat but potentially prevent diseases associated with aging. The involvement of renowned investors like Khosla Ventures and Ahren Innovation Capital underscores the potential of Rubedo’s innovative strategies to make significant impacts in medical science, particularly in improving life quality for aging populations worldwide. This funding could mark a significant milestone in the transition from disease treatment to disease prevention in biotechnology.
